On December 6 These patents currently expire, 2011 and July 30, 2013. If both are granted, the business will need to go for one patent for expansion. AMPYRA is now obtainable by prescription in the United States.. Acorda Therapeutics submits applications to extend patent security for AMPYRA to USPTO Acorda Therapeutics, Inc. AMPYRA was accepted by the U.S. Food and Drug Administration on January 22, 2010 and has seven years of exclusivity in multiple sclerosis based on orphan drug status, which has been verified by the FDA.Logan, Ph.D., Stephanie J. Lee, M.D., M.P.H., Edmund K. Waller, M.D., Ph.D., Daniel J. Weisdorf, M.D., John R. Wingard, M.D., Corey S. Cutler, M.D., M.P.H., Peter Westervelt, M.D., Ph.D., Ann Woolfrey, M.D., Stephen Couban, M.D., Gerhard Ehninger, M.D., Laura Johnston, M.D., Richard T. Maziarz, M.D., Michael A. Pulsipher, M.D., David L. Porter, M.D., Shin Mineishi, M.D., John M. McCarty, M.D., Shakila P. Khan, M.D., Paolo Anderlini, M.D., William I. Bensinger, M.D., Susan F.